<DOC>
	<DOCNO>NCT01613976</DOCNO>
	<brief_summary>The purpose study confirm safety tolerability oral panobinostat ( PAN ) combination fix dose 5-Azacitidine ( 5-Aza ) adult Japanese patient Myelodysplastic Syndromes ( MDS ) , Chronic Myelomonocytic Leukemia ( CMML ) Acute Myeloid Leukemia ( AML ) .</brief_summary>
	<brief_title>A Phase Ib Study Panobinostat ( LBH589 ) Combination With 5-Azacitidine Myelodysplastic Syndromes ( MDS ) , Chronic Myelomonocytic Leukemia ( CMML ) Acute Myeloid Leukemia ( AML ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>1 . Japanese patient candidate treatment 5Aza present one following : intermediate2 highrisk MDS accord International Prognostic Scoring System ( IPSS ) . OR AML multilineage dysplasia maximum 30 % blast ( former RAEBT accord FAB ) OR CMML 2 . Patient ECOG performance status ≤ 2 3 . Patients must follow laboratory value unless elevation consider due MDS leukemia : AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN ; serum creatinine ≤ 1.5 x ULN ; serum bilirubin ( total direct ) ≤ 2 x ULN ; electrolyte panel without clinically relevant abnormality 1 . Patient plan history hematopoietic stemcell transplantation ( HSCT ) 2 . Patients relapsed/refractory AML 3 . Patient receive concurrent anticancer therapy 4 . Patient receive prior treatment deacetylase inhibitor ( DACi ) 5 . Patient receive prior treatment 5Aza 6aza2'deoxycytidine ( decitabine ) 7 . Patient show suspected hypersensitivity 5Aza Mannitol 8 . Patients impaired cardiac function 9 . Patient take medication relative risk prolong QT interval induce Torsade de pons treatment discontinue switched different medication prior start study treatment 10 . Patients clinical evidence relevant mucosal internal bleeding 11 . Patient concurrent severe and/or uncontrolled medical condition Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>MDS</keyword>
	<keyword>Chronic Myelomonocytic Leukemia</keyword>
	<keyword>CMML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Panobinostat</keyword>
	<keyword>LBH589</keyword>
	<keyword>5-Aza</keyword>
	<keyword>Azacitidine</keyword>
</DOC>